Beauty Health (NASDAQ:SKIN - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02, Zacks reports. Beauty Health had a negative return on equity of 44.83% and a negative net margin of 8.11%.
Beauty Health Price Performance
NASDAQ:SKIN traded up $0.06 during trading hours on Wednesday, reaching $1.42. The company had a trading volume of 649,943 shares, compared to its average volume of 1,325,838. The company has a quick ratio of 5.57, a current ratio of 6.56 and a debt-to-equity ratio of 9.23. The stock has a 50-day moving average of $1.59 and a two-hundred day moving average of $1.57. Beauty Health has a one year low of $0.91 and a one year high of $5.17. The firm has a market capitalization of $176.25 million, a PE ratio of -3.38 and a beta of 0.84.
Wall Street Analysts Forecast Growth
Separately, Canaccord Genuity Group lifted their price target on shares of Beauty Health from $1.25 to $1.75 and gave the company a "hold" rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $2.55.
Check Out Our Latest Stock Analysis on SKIN
About Beauty Health
(
Get Free Report)
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Beauty Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beauty Health wasn't on the list.
While Beauty Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
